Inhibition of EZH2 Alleviates SAHA-induced Senescence-associated Secretion Phenotype in Small Cell Lung Cancer Cells

Overview

Journal Cell Death Discov

Date 2023 Aug 5

PMID 37543653

Authors

Sun-Hyok Kong

Lie Ma

Qingxia Yuan

Xiangxiang Liu

Yu Han

Weifang Xiang

Dong-Xu Liu

Yu Zhang

Jun Lu

Affiliations

Soon will be listed here.

Abstract

Chemotherapy has been widely used in small cell lung cancer (SCLC) treatment in the past decades. However, SCLC is easy to recur after chemotherapy. The senescence of cancer cells during chemotherapy is one of the effective therapeutic strategies to inhibit the progression of cancer. Nevertheless, the senescence-associated secretion phenotype (SASP) promotes chronic inflammation of the cancer microenvironment and further accelerates the progression of tumors. Therefore, inducing the senescence of cancer cells and inhibiting the production of SASP factors during anticancer treatment have become effective therapeutic strategies to improve the anticancer effect of drugs. Here we reported that SCLC cells treated with an FDA-approved HDAC inhibitor SAHA underwent senescence and displayed remarkable SASP. In particular, SAHA promoted the formation of cytoplasmic chromatin fragments (CCFs) in SCLC cells. The increased CCFs in SAHA-treated SCLC cells were related to nuclear porin Tpr, which activated the cGAS-STING pathway, and promoted the secretion of SASP in cancer cells. Inhibition of EZH2 suppressed the increase of CCFs in SAHA-treated SCLC cells, weakened the production of SASP, and increased the antiproliferative effect of SAHA. Overall, our work affords new insight into the secretion of SASP in SCLC and establishes a foundation for constructing a new therapeutic strategy for SCLC patients.

Citing Articles

Dissociation between the expression of cGAS/STING and a senescence-associated signature in colon cancer.

Al Shboul S, Abu Al Karsaneh O, Alrjoub M, Al-Qudah M, El-Sadoni M, Alhesa A Int J Immunopathol Pharmacol. 2025; 39:3946320251324821.

PMID: 40070172 PMC: 11898089. DOI: 10.1177/03946320251324821.

Epigenetic developmental mechanisms underlying sex differences in cancer.

Rubin J, Abou-Antoun T, Ippolito J, Llaci L, Marquez C, Wong J J Clin Invest. 2024; 134(13).

PMID: 38949020 PMC: 11213507. DOI: 10.1172/JCI180071.

Role and potential therapeutic value of histone methyltransferases in drug resistance mechanisms in lung cancer.

Zhang L, Zhang X, Shi Y, Ni Y, Fei J, Jin Z Front Oncol. 2024; 14:1376916.

PMID: 38525426 PMC: 10957659. DOI: 10.3389/fonc.2024.1376916.

References

Krull S, Dorries J, Boysen B, Reidenbach S, Magnius L, Norder H . Protein Tpr is required for establishing nuclear pore-associated zones of heterochromatin exclusion. EMBO J. 2010; 29(10):1659-73. PMC: 2876962. DOI: 10.1038/emboj.2010.54. View

Yang H, Wang H, Ren J, Chen Q, Chen Z . cGAS is essential for cellular senescence. Proc Natl Acad Sci U S A. 2017; 114(23):E4612-E4620. PMC: 5468617. DOI: 10.1073/pnas.1705499114. View

Hernandez-Segura A, Nehme J, Demaria M . Hallmarks of Cellular Senescence. Trends Cell Biol. 2018; 28(6):436-453. DOI: 10.1016/j.tcb.2018.02.001. View

West A, Johnstone R . New and emerging HDAC inhibitors for cancer treatment. J Clin Invest. 2014; 124(1):30-9. PMC: 3871231. DOI: 10.1172/JCI69738. View

Murai F, Koinuma D, Shinozaki-Ushiku A, Fukayama M, Miyaozono K, Ehata S . EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway. Cell Discov. 2016; 1:15026. PMC: 4860843. DOI: 10.1038/celldisc.2015.26. View

Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M . Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther. 2008; 7(7):1923-30. DOI: 10.1158/1535-7163.MCT-07-2140. View

Oronsky B, Reid T, Oronsky A, Carter C . What's New in SCLC? A Review. Neoplasia. 2017; 19(10):842-847. PMC: 5596356. DOI: 10.1016/j.neo.2017.07.007. View

Elzi D, Lai Y, Song M, Hakala K, Weintraub S, Shiio Y . Plasminogen activator inhibitor 1--insulin-like growth factor binding protein 3 cascade regulates stress-induced senescence. Proc Natl Acad Sci U S A. 2012; 109(30):12052-7. PMC: 3409757. DOI: 10.1073/pnas.1120437109. View

Lessard F, Igelmann S, Trahan C, Huot G, Saint-Germain E, Mignacca L . Senescence-associated ribosome biogenesis defects contributes to cell cycle arrest through the Rb pathway. Nat Cell Biol. 2018; 20(7):789-799. DOI: 10.1038/s41556-018-0127-y. View

10.

Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A . Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther. 2009; 8(11):3075-87. DOI: 10.1158/1535-7163.MCT-09-0254. View

11.

Wang B, Kohli J, Demaria M . Senescent Cells in Cancer Therapy: Friends or Foes?. Trends Cancer. 2020; 6(10):838-857. DOI: 10.1016/j.trecan.2020.05.004. View

12.

Kim S, Fernandez-Martinez J, Nudelman I, Shi Y, Zhang W, Raveh B . Integrative structure and functional anatomy of a nuclear pore complex. Nature. 2018; 555(7697):475-482. PMC: 6022767. DOI: 10.1038/nature26003. View

13.

Calcinotto A, Kohli J, Zagato E, Pellegrini L, Demaria M, Alimonti A . Cellular Senescence: Aging, Cancer, and Injury. Physiol Rev. 2019; 99(2):1047-1078. DOI: 10.1152/physrev.00020.2018. View

14.

Richon V, Garcia-Vargas J, Hardwick J . Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett. 2009; 280(2):201-10. DOI: 10.1016/j.canlet.2009.01.002. View

15.

Kalemkerian G, Loo B, Akerley W, Attia A, Bassetti M, Boumber Y . NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018; 16(10):1171-1182. DOI: 10.6004/jnccn.2018.0079. View

16.

Lemjabbar-Alaoui H, Hassan O, Yang Y, Buchanan P . Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015; 1856(2):189-210. PMC: 4663145. DOI: 10.1016/j.bbcan.2015.08.002. View

17.

Ma J, Goryaynov A, Sarma A, Yang W . Self-regulated viscous channel in the nuclear pore complex. Proc Natl Acad Sci U S A. 2012; 109(19):7326-31. PMC: 3358865. DOI: 10.1073/pnas.1201724109. View

18.

Coppe J, Desprez P, Krtolica A, Campisi J . The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010; 5:99-118. PMC: 4166495. DOI: 10.1146/annurev-pathol-121808-102144. View

19.

Boumendil C, Hari P, Olsen K, Carlos Acosta J, Bickmore W . Nuclear pore density controls heterochromatin reorganization during senescence. Genes Dev. 2019; 33(3-4):144-149. PMC: 6362808. DOI: 10.1101/gad.321117.118. View

20.

Taniguchi H, Caeser R, Chavan S, Zhan Y, Chow A, Manoj P . WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 2022; 39(7):110814. PMC: 9449677. DOI: 10.1016/j.celrep.2022.110814. View